CRIS Current Research Information System

NANNI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.193
AS - Asia 4.758
EU - Europa 3.935
AF - Africa 340
SA - Sud America 236
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 15.478
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.092
VN - Vietnam 1.531
CN - Cina 1.243
SG - Singapore 1.100
IT - Italia 960
GB - Regno Unito 884
DE - Germania 471
HK - Hong Kong 321
SE - Svezia 314
FR - Francia 221
RU - Federazione Russa 206
IN - India 185
UA - Ucraina 180
BR - Brasile 167
CH - Svizzera 143
IE - Irlanda 122
NL - Olanda 117
CI - Costa d'Avorio 113
ZA - Sudafrica 106
JP - Giappone 90
CA - Canada 71
EE - Estonia 58
FI - Finlandia 57
TG - Togo 56
KR - Corea 53
BG - Bulgaria 44
BE - Belgio 43
BD - Bangladesh 35
AR - Argentina 33
ID - Indonesia 26
SC - Seychelles 26
PH - Filippine 25
TH - Thailandia 21
JO - Giordania 19
MX - Messico 19
TR - Turchia 19
IQ - Iraq 18
LT - Lituania 17
PL - Polonia 16
RO - Romania 15
EC - Ecuador 13
TW - Taiwan 13
AT - Austria 12
NG - Nigeria 11
PK - Pakistan 11
EG - Egitto 10
CL - Cile 9
ES - Italia 9
AU - Australia 8
GR - Grecia 8
HR - Croazia 8
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 5
CO - Colombia 5
DK - Danimarca 5
IR - Iran 5
MA - Marocco 5
EU - Europa 4
MY - Malesia 4
UZ - Uzbekistan 4
VE - Venezuela 4
AZ - Azerbaigian 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
GH - Ghana 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LB - Libano 2
LI - Liechtenstein 2
LV - Lettonia 2
MD - Moldavia 2
TN - Tunisia 2
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
ET - Etiopia 1
GI - Gibilterra 1
GP - Guadalupe 1
HU - Ungheria 1
IL - Israele 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NP - Nepal 1
NR - Nauru 1
NZ - Nuova Zelanda 1
Totale 15.467
Salva come PNG Salva come JPEG
Città #
Singapore 739
Southend 719
Fairfield 685
Ashburn 643
Chandler 528
Ho Chi Minh City 335
Wilmington 317
Woodbridge 310
Houston 309
Hong Kong 306
Ann Arbor 296
Hanoi 284
San Jose 265
Seattle 256
Bologna 252
Cambridge 205
Dong Ket 191
Santa Clara 186
Shanghai 182
Princeton 175
Beijing 137
Boardman 127
Hefei 125
Dublin 122
Jacksonville 116
Abidjan 113
Bern 113
Council Bluffs 83
Dallas 81
Lauterbourg 77
Nanjing 75
Tokyo 74
Westminster 74
Los Angeles 73
New York 68
Padova 66
Milan 62
Lomé 56
Berlin 55
Bremen 50
Haiphong 48
Guangzhou 46
Jinan 44
Helsinki 43
Sofia 43
Buffalo 42
Saint Petersburg 42
Brussels 41
Seoul 39
San Diego 37
Shenyang 37
Redwood City 36
Da Nang 35
Frankfurt am Main 34
Johannesburg 34
London 30
Redmond 29
Nanchang 28
Phoenix 28
Redondo Beach 28
Changsha 27
São Paulo 27
Turin 27
Hebei 26
Tianjin 25
Mülheim 24
Casalecchio di Reno 23
Rome 23
Falkenstein 22
Jakarta 22
Toronto 22
Amsterdam 21
Ottawa 21
Amman 19
Jiaxing 19
Hải Dương 18
Zhengzhou 18
Falls Church 17
Bulle 15
Mahé 15
Atlanta 14
Bengaluru 14
Biên Hòa 14
Des Moines 14
Montreal 14
Hangzhou 13
Can Tho 12
Shijiazhuang 12
Haikou 11
Yubileyny 11
Abeokuta 10
Bắc Giang 10
Bến Tre 10
Nuremberg 10
Orem 10
Stockholm 10
Verona 10
Warsaw 10
Bühl 9
Dearborn 9
Totale 10.332
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 432
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 386
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 340
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 324
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 271
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 267
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 259
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 252
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors 252
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 247
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 239
Rethinking herpes simplex virus: the way to oncolytic agents. 238
Virus-like particle display of HER2 induces potent anti-cancer responses 232
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 230
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 228
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 219
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 219
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 216
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 213
CD99 Acts as an Oncosuppressor in Osteosarcoma. 212
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 211
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay 210
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 206
Cancer immunoprevention: from mice to early clinical trials 205
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 201
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 199
In silico modeling and in vivo efficacy of cancer preventive vaccinations 199
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 198
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 195
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 193
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 191
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 188
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 188
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 187
Antimetastatic activity of a preventive cancer vaccine. 186
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 185
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 185
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 185
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 184
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 180
Oncolytic herpes virus retargeted to HER-2. 179
Herpesviruses as oncolytic agents 179
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 178
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 177
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 177
Modeling the competition between lung metastases and the immune system using agents. 176
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 176
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 175
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 174
Immunoprevention and immunotherapy of mammary carcinoma 172
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 169
Vaccines for tumour prevention 168
The Promise of Preventive Cancer Vaccines 168
Immunological prevention of a multigene cancer syndrome 164
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 161
The molecular basis of herpesviruses as oncolytic agents. 160
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 159
Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. 158
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 157
New target antigens for cancer immunoprevention 153
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 152
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 150
Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent 149
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 149
Preclinical HER-2 Vaccines: From Rodent to Human HER-2 148
Preclinical vaccines against mammary carcinoma. 148
2011: the immune hallmarks of cancer 147
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 146
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 146
Molecular and cellular biology of rhabdomyosarcoma 143
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 142
Insulin-like growth factor binding protein 3 as an anti-cancer molecule in Ewing's sarcoma. 140
Vaccines and other immunological approaches for cancer immunoprevention 136
Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer 135
Immunoprevention 122
CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine. 121
Cancer biology, what we know and what we don't know. 118
Methods of treating bone cancer 114
null 99
Immunoprevention of cancer 99
Vaccini contro i tumori 97
Immunotherapy 94
Cancer immunoprevention 84
Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response 75
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts 67
null 62
Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells. 53
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture 24
Totale 15.792
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.550
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.550
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021415 0 0 0 0 0 0 0 0 0 0 0 415
2021/20221.689 161 67 145 82 155 110 51 111 73 115 367 252
2022/20231.986 233 238 106 271 137 137 65 104 261 106 161 167
2023/2024637 22 75 45 51 37 75 35 217 10 27 14 29
2024/20251.954 153 223 154 102 334 134 125 85 22 134 93 395
2025/20264.657 496 455 395 350 475 245 403 145 961 431 209 92
Totale 15.792